Journal of Translational Medicine, published by BMC in the United Kingdom, stands at the forefront of biomedical research, bridging the gap between laboratory discoveries and clinical applications. Established in 2003 as an Open Access journal, it has garnered significant recognition, achieving a Q1 quartile ranking in both Biochemistry, Genetics and Molecular Biology and Medicine categories as of 2023. With an impressive Scopus rank of 38 out of 636 in General Medicine and 33 out of 221 in General Biochemistry, Genetics and Molecular Biology, the journal is committed to disseminating high-quality, peer-reviewed research that impacts healthcare and informs clinical practices. By facilitating free access to groundbreaking studies, the Journal of Translational Medicine aims to enhance collaboration among researchers, professionals, and students in the scientific community, fostering advancements in translational research well into the future.

Welcome to Molecular Neurobiology, the premier journal dedicated to the exploration of the molecular mechanisms underlying nervous system function and pathophysiology. Published by Springer, this journal provides an essential platform for disseminating high-quality research in the rapidly evolving fields of Cellular and Molecular Neuroscience and Neurology, boasting an impressive impact factor that reflects its esteemed position within the academic community. With its ranking in the Q1 and Q2 quartiles for various neuroscience categories, Molecular Neurobiology stands at the forefront of groundbreaking discoveries, showcasing innovative studies that bridge basic science and clinical application. Researchers and professionals are invited to contribute to its rich portfolio, which spans from fundamental insights into cellular processes to advanced therapeutic strategies. Although Molecular Neurobiology does not operate as an Open Access journal, its influential body of work remains accessible through institutional and personal subscriptions. As we converge from 1987 to 2024, we continue to aim for excellence, seeking to catalyze progress in understanding neurological diseases and enhance the scientific dialogue within the neuroscience community.

Aging-US is a premier peer-reviewed journal dedicated to advancing the field of aging research and cell biology. Published by IMPACT JOURNALS LLC, this journal serves as a vital resource for researchers and professionals exploring the biological mechanisms of aging and their implications for health and disease. With a commendable impact factor reflected in its 2023 Scopus rankings, where it stands at Rank #10/38 in the category of Aging and Rank #63/285 in Cell Biology, Aging-US exemplifies rigorous scientific excellence. Its open access policy enhances accessibility, fostering a wider dissemination of knowledge in both academic and clinical settings. Spanning from 2009 to 2024, the journal provides a platform for groundbreaking studies and innovative methodologies, ensuring that it remains at the forefront of the dynamic conversations surrounding aging and cellular biology. Engage with Aging-US to contribute to the evolving narratives of longevity and cellular health.

Molecular Therapy Oncolytics is an esteemed Open Access journal published by CELL PRESS, focusing on cutting-edge research in the fields of oncology, molecular medicine, and pharmacology. Established in 2014, the journal has quickly gained a prominent position in the academic community, reflected in its impressive Q1 and Q2 rankings across various categories including Cancer Research, Molecular Medicine, and Pharmacology. With an impactful presence in the UK and a strong international readership, it aims to disseminate significant advancements in therapeutic strategies targeted at cancer treatment and management. By providing a platform for peer-reviewed research, Molecular Therapy Oncolytics plays a critical role in bridging the gap between scientific innovation and clinical application, making it an invaluable resource for researchers, healthcare professionals, and students striving to contribute to the evolving landscape of oncology.

JOURNAL OF MOLECULAR MEDICINE (JMM) is a premier publication dedicated to advancing the field of molecular medicine, encompassing critical areas such as drug discovery, genetics, and biochemistry. Published by Springer Heidelberg in Germany, this influential journal has established its significance within the academic community, achieving an impressive Q1 ranking across multiple categories as of 2023, including Drug Discovery, Clinical Genetics, and Molecular Medicine. With a focus on publishing high-quality research and novel insights, JMM appeals to a diverse audience of researchers, professionals, and students passionate about the molecular underpinnings of health and disease. The journal, which has seen a convergence of relevant research spanning from 1976 to 2024, is instrumental in showcasing groundbreaking studies that push the boundaries of knowledge in molecular therapeutics and biomedical science. While it does not offer open access, the rigor of its peer-reviewed content ensures that each publication is a valuable addition to the scientific discourse surrounding molecular medicine. For comprehensive studies and reviews that highlight the intersection of molecular biology and clinical application, look no further than JOURNAL OF MOLECULAR MEDICINE.

MOLECULAR MEDICINE, published by SPRINGER, is a leading scholarly journal dedicated to advancing the fields of genetics and molecular biology with a focus on clinical applications. Since its inception in 1994, it has evolved to become a pivotal platform for disseminating innovative research findings, achieving a remarkable Q1 ranking in multiple categories, including Genetics, Molecular Biology, and Molecular Medicine as of 2023. Featuring an Open Access model since 2000, the journal ensures that cutting-edge research is freely available to the global scientific community, facilitating collaboration and knowledge exchange. With a commitment to high-quality peer-reviewed content, MOLECULAR MEDICINE serves as an essential resource for researchers, healthcare professionals, and students seeking to stay at the forefront of molecular research and its implications for medical science. For those interested in contributing to or accessing vital research in this dynamic field, MOLECULAR MEDICINE stands out as a premier choice.

Advanced Biology, published by WILEY-V C H VERLAG GMBH, serves as a premier platform where innovative research and scientific breakthroughs in the fields of biochemistry, genetics, and molecular biology converge. Established in 2021, this journal has rapidly ascended to prominence, securing Q1 rankings in its primary categories, including general biochemistry and biomedical engineering, and a solid Q2 ranking in biomaterials. With an ISSN of 2701-0198 and an emphasis on open access, Advanced Biology ensures that rigorous peer-reviewed research is accessible to a global audience, enhancing visibility and fostering collaboration among researchers, professionals, and students alike. By 2024, it aims to continually elevate scientific understanding and innovation, catering to the growing interdisciplinary nature of these critical fields. With Scopus rankings placing it amongst the top quartiles in its disciplines, Advanced Biology is poised to make significant contributions to the future of life sciences.

Science Immunology, published by the American Association for the Advancement of Science, is a leading journal in the field of immunology, recognized for its significant impact and rigor in advancing our understanding of immune responses and complex diseases. With an impressive impact factor that places it in the Q1 category of both immunology and allergy, as well as miscellaneous medicine, this journal is ranked #7 and #8 in their respective Scopus categories, reflecting its high-quality research output. Since its inception in 2016, Science Immunology has been at the forefront of interdisciplinary immunological research, fostering crucial insights that link immunology with pressing health challenges. The journal is committed to providing open access to its content, ensuring that groundbreaking findings are accessible to a global audience of researchers, professionals, and students. Its anthology not only addresses fundamental immunological mechanisms but also enhances the dialogue on translational applications and therapeutic interventions, solidifying its position as an essential resource within the scientific community.

Current Molecular Pharmacology, published by Bentham Science Publishers, is a prominent journal focused on the dynamic fields of pharmacology, drug discovery, and molecular medicine. With an ISSN of 1874-4672 and an E-ISSN of 1874-4702, this journal aims to disseminate cutting-edge research and review articles that showcase innovative methodologies and groundbreaking findings from 2008 through 2024. Holding a respectable Q3 category ranking in Drug Discovery, Molecular Medicine, and Pharmacology for 2023, Current Molecular Pharmacology serves as an essential platform for both established researchers and emerging scholars to share their insights. The journal is indexed in Scopus with its relevant ranks catering to pharmacology and molecular biology, ensuring it reaches a wide array of professionals, researchers, and students in the field. As a contributor to advancing pharmacological sciences, this journal provides invaluable access to the latest advancements and fosters ongoing dialogue in molecular pharmacology, positioning itself as a key resource in the exploration of therapeutic agents and their interactions.

EXPERIMENTAL AND MOLECULAR PATHOLOGY, a distinguished journal published by Academic Press Inc Elsevier Science, is recognized for its significant contributions to the fields of pathology, clinical biochemistry, and molecular biology. With an ISSN of 0014-4800 and an E-ISSN of 1096-0945, this journal provides a platform for the dissemination of high-quality research articles, reviews, and experimental studies that deepen our understanding of disease mechanisms and diagnostic pathways. Since its inception in 1962 and through its converged publication years, the journal has consistently maintained a solid impact in the academic community, achieving high Scopus rankings—ranked #15 in the field of Pathology and Forensic Medicine and #22 in Clinical Biochemistry, showcasing a commendable percentile standing of 93rd and 81st respectively in 2023. The journal is accessible through various academic libraries and institutional subscriptions, making it an essential resource for researchers, professionals, and students committed to advancing knowledge in these critical areas. With a categorization that includes Q1 rankings in Pathology and Forensic Medicine, EXPERIMENTAL AND MOLECULAR PATHOLOGY stands as a prominent venue for pioneering scientific inquiry and collaborative advancement in molecular diagnostics and therapeutic strategies.